Zhou Q, Li J, Cang SD, Lin JX, et al. FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naive NSCLC Patients Harboring EGFR 21L858R Mutation. Clin Lung Cancer 2025;26:152-157.
PMID: 39424513